Ronan J. Kelly, MD, MBA

Articles

The Future for HER2-Directed ADCs

August 29th 2024

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

August 29th 2024

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Dr Kelly on ctDNA Dynamics Following Neoadjuvant Immunotherapy in GEJ Cancer

May 20th 2024

Ronan J. Kelly, MD, MBA, FASCO, discusses the predictive value of ctDNA following neoadjuvant immunotherapy in resectable gastroesophageal cancer.

Dr. Kelly on Trials Evaluating Frontline Immunotherapy Combinations in ESCC

February 23rd 2023

Ronan J. Kelly, MD, MBA, discusses the variety of clinical trials investigating immunotherapy with or without chemotherapy in patients with esophageal squamous cell carcinoma.

Rapid Readout: T-DXd in Patients With HER2+ Unresectable or Metastatic Gastric or GEJ Following a Trastuzumab-Containing Regimen

October 27th 2021

Ronan Kelly, MD, MBA, discusses data from the presentation “Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.” (Van Cutsem et al, ESMO 2021, LBA55)

Dr. Kelly on the Safety Profile of Adjuvant Nivolumab in Resected Esophageal/GEJ Cancer

January 14th 2021

Ronan J. Kelly, MD, MBA, discusses the safety profile of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

September 21st 2020

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

Dr. Kelly on the Outlook of ALK-Positive NSCLC

May 14th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Kelly Discusses the Treatment of Patients With ALK+ NSCLC

May 7th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Kelly on the Benefit of Immunotherapy in Stage III NSCLC

May 2nd 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).